Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone immune effects in secondary progressive multiple sclerosis
NL-OMON26011Not yet recruiting
- Sponsor
- Orbis Medical Center Department of Neurology
- Start
- Mar 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mitoxantrone in secondary-progressive multiple sclerosis (SPMS), sponsored by Orbis Medical Center Department of Neurology. Primary endpoints: T-cell compartment, B-cell compartment and 4 more. Planned start Mar 2010; status: not yet recruiting.
02
Drugs
mitoxantrone
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NL-OMON26011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26011.